News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
687,900 Results
Type
Article (39145)
Company Profile (283)
Press Release (648472)
Section
Business (203901)
Career Advice (1996)
Deals (35371)
Drug Delivery (89)
Drug Development (80846)
Employer Resources (168)
FDA (16099)
Job Trends (14808)
News (344641)
Policy (32451)
Tag
Academia (2530)
Alliances (49184)
Alzheimer's disease (1257)
Approvals (16051)
Artificial intelligence (144)
Bankruptcy (352)
Best Places to Work (11581)
Biotechnology (200)
Breast cancer (188)
Cancer (1365)
Cardiovascular disease (110)
Career advice (1664)
Cell therapy (281)
Clinical research (64692)
Collaboration (482)
Compensation (260)
COVID-19 (2541)
C-suite (108)
Data (1389)
Diabetes (172)
Diagnostics (6171)
Earnings (84892)
Employer resources (146)
Events (110005)
Executive appointments (394)
FDA (16769)
Funding (426)
Gene therapy (195)
GLP-1 (597)
Government (4333)
Healthcare (18693)
Infectious disease (2633)
Inflammatory bowel disease (111)
Interviews (309)
IPO (16339)
Job creations (3625)
Job search strategy (1418)
Layoffs (418)
Legal (7861)
Lung cancer (197)
Lymphoma (98)
Manufacturing (206)
Medical device (13211)
Medtech (13216)
Mergers & acquisitions (19192)
Metabolic disorders (452)
Neuroscience (1577)
NextGen Class of 2024 (6500)
Non-profit (4467)
Northern California (1693)
Obesity (258)
Opinion (183)
Patents (117)
People (56455)
Phase I (20119)
Phase II (28493)
Phase III (21237)
Pipeline (514)
Postmarket research (2560)
Preclinical (8545)
Radiopharmaceuticals (236)
Rare diseases (259)
Real estate (5890)
Regulatory (21666)
Research institute (2310)
Resumes & cover letters (349)
Southern California (1461)
Startups (3562)
United States (15142)
Vaccines (563)
Weight loss (181)
Date
Last 7 days (579)
Last 30 days (2250)
Last 365 days (35162)
2024 (35004)
2023 (40077)
2022 (51173)
2021 (55711)
2020 (54086)
2019 (46541)
2018 (35019)
2017 (32110)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (195)
Asia (37267)
Australia (6087)
California (3810)
Canada (1449)
China (304)
Colorado (171)
Connecticut (176)
Europe (79825)
Florida (533)
Georgia (135)
Illinois (384)
Indiana (224)
Maryland (626)
Massachusetts (2959)
Michigan (172)
Minnesota (290)
New Jersey (1100)
New York (1080)
North Carolina (742)
Northern California (1693)
Ohio (146)
Pennsylvania (923)
South America (1091)
Southern California (1461)
Texas (547)
Utah (108)
Washington State (399)
687,900 Results for "invivoscribe inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
Invivoscribe Partners with Complete Genomics to Develop and Commercialize Biomarker Tests for Oncology and Cancer Research
Invivoscribe and Complete Genomics announced that they had entered a partnership to develop and commercialize biomarker tests on Complete Genomics’ NGS platforms.
June 2, 2023
·
3 min read
Policy
Invivoscribe Announces IVDR Approval of the LeukoStrat CDx FLT3 Mutation Assay
We are pleased to announce that Invivoscribe’s LeukoStrat® CDx FLT3 Mutation Assay has been approved by BSI and the EMA as a Class C CDx assay, meeting the stringent new IVDR 2017/746) requirements.
May 11, 2023
·
4 min read
Policy
Invivoscribe Announces FDA Approval of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with FLT3-ITD Positive AML for Treatment with VANFLYTA
Invivoscribe is excited to announce that the LeukoStrat® CDx FLT3 Mutation Assay has been approved by the U.S. Food and Drug Administration to aid in the selection of patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia who may be eligible to receive treatment with Daiichi Sankyo’s VANFLYTA®.
July 21, 2023
·
3 min read
Biotech Beach
Invivoscribe Announces Updated Reimbursement for the LeukoStrat CDx FLT3 Mutation Assay to Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible for VANFLYTA in Japan
Invivoscribe is pleased to announce that their LeukoStrat CDx FLT3 Mutation Assay® has received updated reimbursement by Japan’s Ministry of Health, Labor and Welfare to aid in the selection of patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia who may be eligible to receive treatment with Daiichi Sankyo’s VANFLYTA®.
May 25, 2023
·
2 min read
Business
Hitachi High-Tech and Invivoscribe partner to advance molecular diagnostics and precision medicine
Hitachi High-Tech Corporation (“Hitachi High-Tech”) has entered into a strategic partnership (the Partnership) with Invivoscribe, Inc. (“Invivoscribe”), a global provider of blood cancer testing kits and services, by undertaking a minority investment-based, third-party allotment of shares.
May 9, 2022
·
4 min read
Press Releases
ABS Bio, Inc. announces strategic investment by 3 Boomerang Capital
◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.
November 14, 2024
·
1 min read
Business
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio’s Investigational Compound Being Developed for Patients with AML
Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider of diagnostic kits and services for oncology, announced their agreement to develop a companion diagnostic for use with Kronos Bio’s investigational therapy, entospletinib.
August 16, 2022
·
7 min read
Press Releases
Bloom Burton & Co. Inc. Announces Changes to Holdings in Satellos Bioscience Inc.
December 20, 2024
·
2 min read
Press Releases
TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.
December 12, 2024
·
19 min read
Press Releases
BRIJ Medical, Inc. Awarded Breakthrough Technology Agreement in the Non-Invasive Skin Closure Category with Premier, Inc.
December 17, 2024
·
2 min read
1 of 68,790
Next